A new option proves effective for patients with HER2+ early breast cancer with residual disease after neoadjuvant therapy.
Breast Cancer Program Launches Tumor Board Webcast Video Series
Cleveland Clinic’s multidisciplinary approach to cancer care is demonstrated in the new Tumor Board webcast video series. The series launches with an HER2-positive breast cancer case.
Unique HER2 Trial Uses New Targeted Drug Therapy
A unique trial will test the combination of two powerful and targeted breast cancer drugs, determining their safety and tolerability in Phase I and the overall response rate in Phase II.